ReachMD

Episodes 1-8 of 8

• • 

    

    D. Ross Camidge, MD, PhD

    Peer

  • 

    

    Luis Paz-Ares, MD, PhD

    Peer

  3

  

  RestartResume

  Acquired Resistance to Targeted Therapy of NSCLC: A Global Perspective

• • 

    

    Everett E. Vokes, MD

    Peer

  • 

    

    D. Ross Camidge, MD, PhD

    Peer

  1

  

  RestartResume

  The Changing Landscape of NSCLC: MET Inhibitors

• • 

    

    Mark A. Socinski, MD

    Peer

  • 

    

    Ming-Sound Tsao, MD, FRCPC

    Peer

  4

  

  RestartResume

  How to Approach Liquid Biopsy in the Treatment of NSCLC

• • 

    

    Peter H. O'Donnell, MD

    Peer

  • 

    

    Daniel P. Petrylak, MD

    Peer

  7

  

  RestartResume

  Emerging Treatment Considerations in Metastatic Urothelial Cancer

• • 

    

    Andrew Epstein, MD

    Peer

  4

  

  RestartResume

  5 Key Takeaways on Managing Afib in the Post-CABANA Era

• • 

    

    Karen L. Reckamp, MS, MD

    Peer

  • 

    

    Mark A. Socinski, MD

    Peer

  • 

    

    Helena Yu, MD

    Peer

  4

  

  RestartResume

  Advanced/Metastatic NSCLC Treatment: Advancements for Patients Without Target...

• • 

    

    Mark A. Socinski, MD

    Peer

  3

  

  RestartResume

  Optimizing Immunotherapy in NSCLC: Updates from Trials on Agents Targeting PD-L1

• • 

    

    Robert Mocharnuk, MD

    Peer

  • 

    

    Ingrid A. Mayer, MD

    Peer

  2

  

  RestartResume

  HR+/HER2-Negative Breast Cancer: Revolutions in Precision Medicine with PI3K ...